Skip to main content Back to Top


Asparaginase Erwinia chrysanthemi

Products Affected - Description

    • Erwinaze lyophilized powder for injection, Clinigen, 10,000 unit, vial, 1 count, NDC 57902-0249-01
    • Erwinaze lyophilized powder for injection, Clinigen, 10,000 unit, vial, 5 count, NDC 57902-0249-05

Reason for the Shortage

    • Erwinaze supply disruption is due to ongoing manufacturing issues and capacity constraints at Porton Biopharma Limited (PBL), the sole manufacturer of Erwinaze.
    • Jazz Pharmaceuticals has Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) available through specialty distributors. Additional information can be found at

Available Products

    • Rylaze solution for injection, Jazz Pharmaceuticals, 10 mg, 0.5 mL single dose vial, 3 count, NDC 68727-0900-03

Estimated Resupply Dates

    • Clinigen is not currently supplying Erwinaze and the company cannot estimate when product will be available again.

Implications for Patient Care

    • As of mid-December 2021, Clinigen is no longer providing Erwinase for personal importation


Updated July 18, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. Created October 11, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.



Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.